Liso-cel for lymphoma with minimal residual disease after first treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of large B-cell lymphoma (like diffuse large B-cell or high-grade B-cell).
- You completed 6 cycles of standard first treatment (like R-CHOP) and had a scan showing the cancer is gone or nearly gone.
- After that treatment, a special blood test found a tiny amount of lymphoma DNA still present (called minimal residual disease or MRD).
- Your cancer has not come back (relapsed) or gotten worse (refractory) on scans.
- You are in generally good health with adequate organ function (heart, kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies loncastuximab tesirine (a targeted cancer medicine) given after CAR T-cell therapy when your lymphoma has improved to a partial remission. It aims to reduce the chance of the lymphoma returning after CAR T.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.